바이오의약품 제3자 물류 시장 규모, 점유율, 동향 분석 보고서 : 공급망별, 서비스 유형별, 지역별, 부문별 예측(2025-2030년)

Biopharmaceutical Third-party Logistics Market Growth & Trends:

The global biopharmaceutical third-party logistics market size is anticipated to reach USD 209.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.58% from 2025 to 2030. Increasing demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the market growth. The rising adoption of automated storage and retrieval systems in emerging countries is an ongoing trend among pharmaceutical logistics companies that has gained significant traction.

Furthermore, the trend of shifting from small-molecule drugs to biopharmaceuticals, mainly vaccines and biologics, is projected to drive the market. Since, these small molecule drugs are temperature-sensitive products, demand for temperature-controlled transportation and storage increases and thus, is responsible for the market growth. Technological advancements are among the main factors drivingmarket growth. Technologies, such as mobile cloud solutions, warehouse robotics, and data mining, have changed the overall 3PL space. With the help of these advanced technologies, 3PL companies can maintain the required temperatures for products during transportation.

This will help in reducing complexities in products and human errors. Most biopharmaceutical products are very temperature-sensitive and hence should be stored at the required temperatures. These products require a tracking device for monitoring until delivery. For instance, in May 2023, Tridentify launched a real-time cold chain monitoring system with an innovative feature for continuously tracking the stability and remaining shelf life of products transported in the cold chain. It offers a thorough view of the stability and remaining shelf-life of pharmaceutical products in real-time, which will revolutionize the way companies monitor their operations and manage their stability budgets.

In addition, environmental concerns and costs have caused a slight shift in the means of transport used for commercial products, moving from airway to seaway shipping and in roadways from truck to intermodal (both rail and truck) transport. Intermodal transport is majorly used by these pharmaceutical companies to reduce their carbon footprint. The ongoing trend shows that pharmaceutical manufacturers have shifted to sea freight to reduce the cost and risk factors. Although for cold chain products, the companies still prefer air freight. However, some of the large pharmaceutical companies are planning to transport 70% of their products via ocean freight including cold chain products.

Biopharmaceutical Third-party Logistics Market Report Highlights:

• In 2024, the non-cold chain logistics segment held the largest share of 79.7% in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control.
• The cold chain logistics segment is expected to register a CAGR of 9.40% over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits.
• The warehousing and storage segment held the largest share of 43.3% in 2024. The transportation segment also held a significant revenue share in 2024 due to the lack of internal capabilities of companies.
• North America held the largest revenue share of over 42.53% in 2024 owing to the rise in imports and exports for biopharmaceutical in the country.
• Asia Pacific is expected to register the fastest CAGR of 7.4% over the forecast period owing to the adoption of medicines from the aging population and the shift of drug sales from brand manufacturers to generic.
• The key players are undertaking several strategic initiatives to strengthen their market presence. For instance, in February 2021, Kuehne+Nagel entered into a partnership with China's largest non-state-owned pharma distribution company, Jointown, to enhance its footprint in healthcare & pharmaceutical logistics in China.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Third-Party Logistics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements in logistics
    • 3.2.1.2. Growing applications of reverse logistics in biopharmaceutical industry
    • 3.2.1.3. Rising demand for cold chain logistics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Compliance issues while outsourcing
    • 3.2.2.2. Stringent regulatory framework
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biopharmaceutical Third-Party Logistics Market: Supply Chain Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Biopharmaceutical Third-Party Logistics Market; Supply Chain Movement Analysis
• 4.3. Global Biopharmaceutical Third-Party Logistics Size & Trend Analysis, by Supply Chain, 2018 to 2030 (USD Million)
• 4.4. Cold Chain Logistics
  • 4.4.1. Cold Chain Logistics market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Non-cold Chain Logistics
  • 4.5.1. Non-cold Chain Logistics market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Biopharmaceutical Third-Party Logistics Market: Service Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Biopharmaceutical Third-Party Logistics Market; Service Type Movement Analysis
• 5.3. Global Biopharmaceutical Third-Party Logistics Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
• 5.4. Transportation
  • 5.4.1. Transportation market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Air Freight
    • 5.4.2.1. Air freight market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Sea Freight
    • 5.4.3.1. Sea freight market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Overland
    • 5.4.4.1. Overland market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Warehousing and Storage
  • 5.5.1. Warehousing and storage market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other Services
  • 5.6.1. Other services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Biopharmaceutical Third-Party Logistics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. North America
  • 6.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Competitive scenario
    • 6.3.2.3. Regulatory framework
    • 6.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Competitive scenario
    • 6.3.3.3. Regulatory framework
    • 6.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Competitive scenario
    • 6.3.4.3. Regulatory framework
    • 6.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Competitive scenario
    • 6.4.2.3. Regulatory framework
    • 6.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Competitive scenario
    • 6.4.3.3. Regulatory framework
    • 6.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Competitive scenario
    • 6.4.4.3. Regulatory framework
    • 6.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Competitive scenario
    • 6.4.5.3. Regulatory framework
    • 6.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Competitive scenario
    • 6.4.6.3. Regulatory framework
    • 6.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Competitive scenario
    • 6.4.7.3. Regulatory framework
    • 6.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Competitive scenario
    • 6.4.8.3. Regulatory framework
    • 6.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Competitive scenario
    • 6.4.9.3. Regulatory framework
    • 6.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Competitive scenario
    • 6.5.2.3. Regulatory framework
    • 6.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Competitive scenario
    • 6.5.3.3. Regulatory framework
    • 6.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Competitive scenario
    • 6.5.4.3. Regulatory framework
    • 6.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Competitive scenario
    • 6.5.5.3. Regulatory framework
    • 6.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Competitive scenario
    • 6.5.6.3. Regulatory framework
    • 6.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Thailand
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Competitive scenario
    • 6.5.7.3. Regulatory framework
    • 6.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Competitive scenario
    • 6.6.2.3. Regulatory framework
    • 6.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Competitive scenario
    • 6.6.3.3. Regulatory framework
    • 6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Competitive scenario
    • 6.7.2.3. Regulatory framework
    • 6.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Competitive scenario
    • 6.7.3.3. Regulatory framework
    • 6.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Competitive scenario
    • 6.7.4.3. Regulatory framework
    • 6.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Competitive scenario
    • 6.7.5.3. Regulatory framework
    • 6.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Company Market Position Analysis, 2024
• 7.3. Company Profiles
  • 7.3.1. DHL International GmbH
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Service benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. SF Express
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Service benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. FedEx
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Service benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. United Parcel Service of America, Inc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Service benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Cencora, Inc
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Service benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. DB Schenker
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Service benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Kuehne and Nagel
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Service benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Kerry Logistics Network Limited
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Service benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Agility Public Warehousing Company K.S.C.P.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Service benchmarking
    • 7.3.9.4. Strategic initiatives